Lyramid Ltd and KineraLtd would themselves commercialise their IP including Advangen paying either as applicable for its Midkine for its Evolis range. The present "lifeline" would not be severed. Any other funding if required would be on commercial terms. However, the subsidiaries were never meant to bleed Cellmid. Good point Hobbit2233 I hope I've answered.
- Forums
- ASX - By Stock
- AN1
- Ann: AGM Presentation by CEO
Ann: AGM Presentation by CEO, page-63
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 565639 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 80000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 565639 | 0.006 |
1 | 300000 | 0.005 |
2 | 525000 | 0.004 |
1 | 600000 | 0.003 |
2 | 500000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 80000 | 1 |
0.010 | 157763 | 1 |
0.015 | 340000 | 2 |
0.016 | 100000 | 1 |
0.017 | 110000 | 1 |
Last trade - 16.12pm 03/09/2024 (20 minute delay) ? |
Featured News
AN1 (ASX) Chart |
Day chart unavailable